3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Multiple Myeloma
4
Neoplasms
3
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Stomatitis
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oncology Patients Receiving Chemotherapy
1
Mucositis
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Burkitt Lymphoma
1
Interventions
Radiotherapy
5
angiotensin I (1-7)
4
Cisplatin
4
Injections
3
RRx-001
2
Fibroblast Growth Factor 7
2
tempol
1
hydrated silica gel-based toothpaste
1
golotimod
1
brilacidin
1
apraglutide
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Water
1
Therapeutics
1
Radiotherapy, Intensity-Modulated
1
Lidocaine
1
Drug Therapy
1
Diphenhydramine
1
Betaine
1
2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mucositis
×
Diphenhydramine
×
Clear all
NCT02606994
2019-02-06
TPvsM
Oral Defense, LLC
Phase 2
Terminated
1 enrolled